Dianthus Therapeutics (DNTH) Share-based Compensation (2017 - 2025)

Dianthus Therapeutics' Share-based Compensation history runs 9 years deep, the most recent figure standing at $5.8 million for Q3 2025.

• In Q3 2025, Share-based Compensation rose 50.89% year-over-year to $5.8 million; the TTM figure through Sep 2025 stood at $20.7 million (up 113.7% YoY), while the FY2024 annual figure was $12.9 million, up 344.62% from the prior year.
• Share-based Compensation was $5.8 million for Q3 2025 at Dianthus Therapeutics, up from $5.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $5.8 million in Q3 2025 to a low of $462000.0 in Q2 2023.
• Historically, Share-based Compensation has averaged $2.5 million across 5 years, with a median of $2.1 million in 2021.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation slumped 82.6% in 2022, then surged 571.21% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $2.2 million in 2021, then plunged by 76.5% to $513000.0 in 2022, then soared by 41.52% to $726000.0 in 2023, then surged by 439.67% to $3.9 million in 2024, then jumped by 47.88% to $5.8 million in 2025.
• The last three Share-based Compensation figures came in at $5.8 million (Q3 2025), $5.7 million (Q2 2025), and $5.3 million (Q1 2025), per Business Quant data.